tbuckley/cabot-search huggingface dataset:
SAT0238 Glucocorticoid withdrawal in an inception cohort of lupus nephritis patients
Authors: S Wautier, F Tamirou, S Nieuwland-Husson, FA Houssiau
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Few studies have addressed glucocorticoid (GC) withdrawal in lupus nephritis (LN). Yet, this remains a pivotal issue due to GC-induced side effects on the one hand, and to the risk of relapse on the other hand. <h3>Objectives</h3> We reviewed the data of the Louvain Lupus Nephritis Inception Cohort (LOULUNIC) i): to determine the percentage of patients able to permanently or transiently stop GC; ii): to compare their baseline and follow-up characteristics to patients who never stopped; and iii): to assess the consequences of GC withdrawal. <h3>Methods</h3> Ninety patients with new-onset biopsy-proven LN were included. All were under the care of the same senior physician (FAH) during follow-up. Clinical, pathological and biological data were extracted from our data base. The SLICC/ACR-DI was assessed at last visit. Unpaired t-tests, Mann-Whitney tests and ANOVA were used, as appropriate. <h3>Results</h3> Out of 90 patients with incident LN, 43 (48%) ever stopped GC (group E), of which 32 permanently (group P). Median time to stop GC was 37 months. 47 patients (52%) never stopped GC (group N). At <i>baseline</i>, serum creatinine, uP/C ratio, ISN/RPS classes, activity and chronicity indices did not differ between groups, nor did the mean initial dose of methylprednisolone (MP) (N: 28 mg/d; E: 32 mg/d; P: 31 mg/d), the use of IV MP pulses (82 and 77% in N and E groups, respectively) and of IV cyclophosphamide (81 and 77%, respectively). During the <i>first year</i>, mean (SD) uP/C decreased statistically more in group E compared to group N (<i>p</i>=0.028 by ANOVA), with striking differences at month 3 (N: 1.73±1.87; E: 0.96±1.34; <i>p</i>=0.038 by unpaired t-test). This difference at month 3 was also noticed for group P patients (0.85±0.76; <i>p</i>=0.02 by unpaired t-test). Interestingly, the mean MP dose at month 3 was statistically higher in group E (19±8) and P (20±9) compared to group N (15±6) (<i>p</i>=0.005 by unpaired t-test). At <i>last follow-up</i>, serum creatinine was statistically lower in E and P patients compared to N patients. Eight of the 11 patients from the T group suffered form a renal relapse, justifying restart of GC, after a median time of 30 months. Importantly, SLICC/ACR-DI was significantly lower in E and P patients, compared to N patients (<i>p</i>=0.0068 and 0.0027, respectively). <h3>Conclusions</h3> In half of LN patients, complete GC withdrawal is achievable and in one third it can be maintained long term. As expected, patients able to stop GC display less damage at last followup. Patients who were able to stop GC decreased their proteinuria much more promptly during the first year of treatment. Interestingly, they received more GC within the first 3 months of therapy, thereby suggesting that a higher dose of GC during the first 3 months of treatment might be associated with a higher probability of later GC withdrawal. <h3>Disclosure of Interest</h3> None declared
Registry data show increase in joint replacement surgery
Authors: Susan Mayor
Journal: BMJ (2017)

The number of joint replacement procedures is rising, with a low rate of revisions to replace first time joint implants but a higher risk in younger patients, show the latest figures from the orthopaedic joint replacement register for England, Wales, Northern Ireland, and the Isle of Man.1

“The consistently high number of joint replacement cases submitted per year suggests continuing high levels of patient confidence and clinical performance, in what is a remarkably successful surgical intervention,” said Martyn Porter, medical director of the National Joint Registry and …
Host Genetic Control of the Oral Microbiome in Health and Disease
Authors: Andres Gomez, Josh L. Espinoza, Derek M. Harkins, Pamela Leong, Richard Saffery, Michelle Bockmann, Manolito Torralba, Claire Kuelbs, Rohith Kodukula, Jason Inman, Toby Hughes, Jeffrey M. Craig, Sarah K. Highlander, Marcus B. Jones, Chris L. Dupont, Karen E. Nelson
Journal: Cell Host & Microbe (2017)
SAT0406 Prevalence of vertebral fractures in axial spondyloarthritis. a systematic review of observational studies
Authors: JC Nieto-González, R Cubero, S Castañeda, J Ramírez, L Carmona
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Some studies have described a higher rate of osteoporosis in axial spondyloarthritis (AxSpA). However, there are still some doubts about whether vertebral fractures (VF) should be a concern in AxSpA patients <h3>Objectives</h3> To evaluate the prevalence and incidence of VF in AxSpA <h3>Methods</h3> A systematic review was performed in Medline, Embase and Cochrane Library databases limited to studies published from Jan/2006 to Dec/2015) in Spanish, Italian and English. Search strategy combined synomyms of AxSpA, fractures, plus a filter study type. We selected cross-sectional or longitudinal studies estimating the prevalence and/or incidence of VF in adult AxSpA patients <h3>Results</h3> The search retrieved 3944 references which after screening by title and abstract ended in 90 studies to study in depth. Finally, 12 estudies were included. The majority of the studies evaluated the VF prevalence, and only 2 studies evaluated the incidence of VF. Prevalence estimates depended on VF definitions, varying between 4.1% (clinically diagnosed VF) and 32.4% (morphometric fracture by Genant definition). Table 1 shows all studies included and their data <h3>Conclusions</h3> The published studies that focus on VF in AxSpA are very heterogeneous, but in general showed a slight increase in the VF prevalence. More studies are need focused on VF incidence in AxSpA <h3>Acknowledgements</h3> Funding: This Project was funded by Merck Sharp &amp; Dohme Spain. Merck Sharp &amp; Dohme did not influenced neither the development of the review nor the confection of the abstract. <h3>Disclosure of Interest</h3> None declared
PARE0021 Public and patient involvement at arthritis research uk: ensuring benefit for all
Authors: C Macdonald
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Since 2008, Arthritis Research UK have utilised the valuable experience and perspective of people with arthritis to review and evaluate the research applications we receive, through the USER stakeholder committee. The world of public and patient involvement (PPI) has developed and progressed hugely in that time. So too has Arthritis Research UK, becoming an insight-led charity that can now genuinely say that people with arthritis are at the centre of everything we do, helping those people to be in control, independent and recognised. As such, our approach to PPI must not only meet the new high standards of meaningful PPI set by the research community but also serve to anchor our research activities and the work that we fund in genuine relevance and patient benefit. <h3>Objectives</h3> To present our new approach to involving people with arthritis in the decision-making processes of research and the wider charity. <h3>Methods</h3> We carried out a UK-wide scoping exercise, consisting of questionnaires and one-to-one interviews, of key stakeholder groups and PPI leaders. This included: our funded researchers and centres of excellence; medical research charities; and people with arthritis including ex- and current USER members. The findings were written up in to a report. <h3>Results</h3> The findings of the report highlighted to us that we need to 1) scale up our PPI activities in order to ensure that insight of people with arthritis can be integrated at all stages of the research cycle 2) improve the quality of our PPI ensuring that all the things we do are carried out with clear purpose, that they are meaningful and add mutual value to all involved 3) increase the numbers of people with arthritis in our PPI group to help realise this vision, whilst improving our support, training and guidance processes for those people 4) recognise and support the already excellent PPI activities going on in the musculoskeletal community, and providing resources and training for those also wishing to start or improve PPI activities. <h3>Conclusions</h3> After implementing this new approach for over a 18 months, we are now confident that our research activities and the research we fund, have the utmost relevance and potential benefit to people with arthritis. <h3>Disclosure of Interest</h3> None declared
Evaluating efficacy and safety of paclitaxel polymeric micelle regimen in advanced and metastatic NSCLC patients in Hai Phong Oncology Centre Vietnam.
Authors: Nguyen Lam Hoa
Journal: Journal of Clinical Oncology (2014)

e19085 Background: Cremophor EL, used to enhance drug solubility, may add to paclitaxel’s toxicities such as hypersensitivity reactions or peripheral neuropathy. This is to report the efficacy and safety of Cremophor-Free, Polymeric Micelle Formulation of Paclitaxel ( PAXUS PM or known also as GENEXOL-PM) as a combined chemotherapy with carboplatin in patients with Locally advanced and Metastatic Non Small-Cell Lung Cancer (NSCLC) conducted in Hải Phòng Oncology Centre, Vietnam. Methods: The patients met inclusion/exclusion criteria underwent the tests for the scheduled treatments. After the tests, the Paclitaxel Polymeric Micelle and Carboplatin were administered to the patients. At least 4 cycles every 3 weeks up to 6 cycles were administered, unless definite disease progression was confirmed. After each cycle of the treatment, and prior to the next cycle, the pre-scheduled tests were performed and the safety was evaluated. The efficacy and toxicities were evaluated after the 2 cycles of treatment. Results: In 80 patients with stage IIIB/ IV NSCLC who had not been or had been previously treated with other chemotherapy regimen, received Paclitaxel Polymeric Micelle 230mg/ m2 in 3 hours infusion plus carboplatin AUC 6 on day 1 of every 3-week cycle for a maximum of six cycles. A total of 384 cycles were given with the mean of 4,8 cycles. The clinical responses were PR = 40.7%, SD = 48.2% and PD = 11.1%. The Hematological toxicities were manageable and varied from grade -1 until grade-3 in 80 evaluable patients where the grade-3 of Neutropenia were recorded in 22 patients ( 27.5%). Conclusions: High-dose of the Paclitaxel Polymeric Micelle in combination with Carboplatin showed significant effective with acceptable and manageable toxicities as first line treatment for patients with Locally advanced and Metastatic Non-small cell lung cancer.
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia
Authors: M-A Hospital, A Jacquel, F Mazed, E Saland, C Larrue, J Mondesir, R Birsen, A S Green, M Lambert, P Sujobert, E-F Gautier, V Salnot, M Le Gall, J Decroocq, L Poulain, N Jacque, M Fontenay, O Kosmider, C Récher, P Auberger, P Mayeux, D Bouscary, J-E Sarry, J Tamburini
Journal: Leukemia (2017)
Disappearance of epidermal transglutaminase and IgA deposits from the papillary dermis of patients with dermatitis herpetiformis after a long-term gluten-free diet
Authors: M. Hietikko, K. Hervonen, T. Salmi, T. Ilus, J.J. Zone, K. Kaukinen, T. Reunala, K. Lindfors
Journal: British Journal of Dermatology (2017)

Dermatitis herpetiformis (DH) is an itchy, blistering skin disease characterised by the deposition of granular immunoglobulin A (IgA) in the papillary dermis. It is regarded as the cutaneous manifestation of coeliac disease, an autoimmune-mediated condition affecting the small intestine. In addition to skin symptoms, DH patients have mostly subclinical small-intestinal villous atrophy and crypt hyperplasia or at least coeliac-type inflammatory changes. Moreover, DH patients have specific antibodies targeting epidermal transglutaminase (a.k.a. transglutaminase 3, TG3), the dominant autoantigen in DH 1.

This article is protected by copyright. All rights reserved.
Nonoperative Treatment of Appendicitis—Reply
Authors: Libin Huang, Yuan Li, Zongguang Zhou
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Ipilimumab for advanced, refractory melanoma: A report of the Israeli cohort of expanded access program.
Authors: Ronnie Shapira-Frommer, Frank Stephen, Eytan Ben-Ami, Tamar Hamburger, Gal Markel, Inna Ospovat, Douglas Zippel, Sharon Merims, Sara Apter, Hani Steinberg, Yael Silman-Steiberg, Tamar Peretz, Michal Lotem, Jacob Schachter
Journal: Journal of Clinical Oncology (2013)

e20039 Background: As the first agent to show survival advantage in metastatic melanoma, Ipilimumab (Yervoy, BMS) is being gradually introduced into health services worldwide. It's unique immune mediated side effects requires the incorporation of follow-up guidelines to prevent toxic sequella. We report on safety and efficacy results of refractory melanoma patients (pts) treated on an international expanded access program of Ipilimumab. Methods: Between 4/2010 and 12/2011 183 pts were treated. Pts received Ipilimumab 3 mg/kg q3w for 4 doses. Pts with evidence of clinical benefit at week 12 (CR, PR or SD), were eligible for re-induction upon progression. Results: All pts were pretreated for metastatic disease (median:1 line,range 1-5). 140 pts(77%) had M1c disease, 63 pts(34%) had brain metastasis and 84 (46%) had LDH above ULN, reflecting poor prognostic characteristics of this cohort. Patients received 3.6 doses of Ipilimumab on average. 11% received less than 4 cycles due to toxicity. Grade 3/4 immune-related adverse events were noted in 19.6% with the most common all grades toxicity being diarrhea (17.5%), pruritus (14%) rash (13%) and fatigue (8.7%). Grade 5 toxicity was noted in 4 patients (2%). Five pts were treated with anti TNF antibodies (Infliximab) for steroid resistant toxicity. Objective responses were noted in 16 pts (8.7%;4 CR, 12 PR), 26 pts(14.2%) had stable disease, overall yielding clinical benefit in 23%. Patients with stage IIIc, M1a and M1b were more likely to benefit (52% Vs 23% of the group, p&lt;0.001) as well as patients previously treated by immunotherapy (p=0.026). Median OS was 9.2 months with 1 year survival of 42%. 34 pts (18.6%) are alive beyond 20 months, the majority of them received no further treatment. Factors favoring survival included stage IIIc, M1a and M1b, LDH below ULN and lymphocyte count at week 6 above 1000/ml (p values: &lt;0.001,&lt;0.001, 0.03 respectively). None of the 14 ocular melanoma pts exhibited clinical benefit. Conclusions: Our cohort reflects rapid adoption of this new modality. Ipilimumab had significant clinical benefit, comparable with previous reports, in a heterogenous group of patients, including those with poor prognostic factors.
Abstract 17081: Predicting Outcomes Using an Algorithm Based on Percent Predicted VO2 and Ventilatory Class in Patients With HFrEF: Data From the HF-ACTION Study
Authors: Clinton A Brawner, David E Lanfear, Jonathan K Ehrman, Steven J Keteyian
Journal: Circulation (2016)

Introduction: Despite numerous prognostic variables from a cardiopulmonary exercise (CPX) test, estimating absolute risk that is clinically-relevant among patients with heart failure (HF) remains a...
AB0745 Subclinical atherosclerosis evolution in psoriatic arthritis patients treated with anti-tnf alpha: 5 years follow up
Authors: A Ortolan, M Puato, G Boschetti, M Lorenzin, A Hoxha, L Punzi, R Ramonda
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Psoriatic arthritis (PsA) is associated with increased morbility and mortality and an accelerated atherosclerosis. Influence of anti-TNFalpha treatment (a widely used therapy in PsA) in subclinical atherosclerosis is still unclear. <h3>Objectives</h3> The aim of this study was to evaluate subclinical atherosclerosis progression before, during and after 5 years of anti-TNFalpha treatment. <h3>Methods</h3> Twenty-seven consecutive PsA patients were evaluated before TNF blockers therapy (T0), after 2 years (T1) and after 5 years (T2) of treatment. Subclinical atherosclerosis was evaluated through carotid duplex scanning, analyzing intima-media thickness (IMT) and flow-mediated dilation (FMD). IMT values were expressed as IMT mean (cumulative mean of all the IMT mean in every analyzed carotid segment) and M-MAX (cumulative mean of all the higher IMT in every analyzed carotid segment). Response to therapy was studied by the evaluation of tender and swollen joints (Tj and Sj), DAS 28 (disease activity score), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Metrologic and metabolic data were collected. For the statistical evaluation of parameters over time (T0 vs T1, T1 vs T2) Student9s T test for paired data was used. <h3>Results</h3> From T0 to T1 a deterioration in IMT-mean and M-MAX (p&lt;0.01) was noted. At T2 IMT-mean remained stable, M-MAX worsened further (p&lt;0.05). No significant variation in FMD was observed (Table). Noteworthy, from T0 to T2 systolic blood pressure and Body Mass Index remained stable (p=ns), while diastolic blood pressure decreased (p=0,001). A good response to PsA treatment was confirmed by a significant decrease (T0 vs T1) in Tj, Sj, DAS 28 and CRP (p&lt;0.01); treatment efficacy was preserved from T1 to T2 (p=ns) (Table). <h3>Conclusions</h3> Our data revealed that in patients with PsA, despite treatment with TNF blockers, there is still a gradual, albeit slight progression of subclinical atherosclerosis assessed by ultrasonography. Other inflammatory mechanisms not related to TNF may be responsible of the progression in atherosclerotic disease. <h3>Disclosure of Interest</h3> None declared
FRI0558 Predictors of mortality and re-fracture at 1 and 3years after hip fracture
Authors: L Brites, M Marques, A Daniel, M Santiago, A Marques, J Pereira da Silva
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Osteoporosis is a major health problem, particularly in the elderly, because of fragility fractures and their consequences. Hip fractures (HF) are the most ominous in terms of morbi-mortality. <h3>Objectives</h3> The aim of our work was to establish the current mortality and re-fracture rate at 1 and 3 years after HF, as well as their predictors. <h3>Methods</h3> The study included all patients aged &gt;40 years, admitted to Coimbra University Hospital between May and October 2013 with the diagnosis of HF. Demographic and clinical data related to the fracture episode was collected from medical files. Patients or the caregiver were contacted to assess potential risk factors at baseline and major post-fracture events at 1 and 3 years after the index HF. The mortality and re-fracture rate 1 and 3 years after fracture were calculated. Possible predictor variables were tested by cox regression analysis: age, gender, physiotherapy, number of re-fractures, BMI, parent hip fracture, current smoking, corticotherapy, rheumatoid arthritis, secondary osteoporosis, alcohol, history of falls, anti-osteoporotic treatment, Katz index of independence in activities of daily living and Charlson comorbidity index. All FRAX® variables were defined as established in this algorithm. <h3>Results</h3> A total of 130 patients satisfied the inclusion criteria, with a mean age of 82±8,7 years, 69% being female). Mortality rates were of 30% and 41% at 1 and 3 years after HF respectively (Fig.1). Age, physiotherapy, parent fractured hip, corticotherapy, alcohol consumption (&gt;3/day) and Charlson índex were statistically significant predictors of mortality at 3 years in multivariable analysis (Tab.1). Re-fracture rates at 1 and 3 years after the index fracture was 3,8% and 11% respectively (Fig.1). We were unable to identify any statistically significant predictors of re-fracture. <h3>Conclusions</h3> We concluded that HF have a great impact on the older population, leading to high morbidity and mortality. In our study, age, physiotherapy, parent hip fracture, corticotherapy, alcohol consumption and Charlson índex are related with increasing mortality in patients who suffered a fagility HF. <h3>Disclosure of Interest</h3> None declared
THU0097 Change in self-reported pain reflects psychological and functional state rather than inflammatory burden in united states latinos with established rheumatoid arthritis
Authors: G Karpouzas, E Hernandez, C Cost, S Ormseth
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Pain represents the cardinal complaint in patients with rheumatoid arthritis (RA). It may reflect inflammation, structural damage, or aberrant processing and regulatory mechanisms. <h3>Objectives</h3> We evaluated whether changes in pain reflect inflammatory burden variation or non-inflammatory factors in Latinos with established RA in the United States (US). <h3>Methods</h3> We evaluated 271 patients from a single academic center with complete data in parameters of interest on 2 visits, 12 months apart. Demographics, serologies, swollen and tender joint assessments, sedimentation rate, fatigue-VAS (visual analogue scale), pain-VAS, depression assessment (Patient Health Questionnaire-PHQ9), functional disability (Health Assessment Questionnaire, HAQ-DI), presence of erosions and irreversible articular damage (IAD, including subluxation, fusion, arthrodesis, or prosthesis) were recorded. Principal components factor analysis with varimax rotation determined latent variables of symptom change. Multinomial logistic regression modeling with forward stepwise entry determined parameters associated with clinically meaningful change in pain compared to no change <h3>Results</h3> Two factors met acceptance criteria (Eigenvalues ≥1) with values of 2.57 and 1.31 respectively (Table 1). Following rotation, factor 1 loadings comprised change in fatigue, pain, depression scores, and functional disability, representing non-inflammatory factors. Conversely, factor 2 encompassed changes in tender and swollen joints and ESR, representing inflammation. Clinically relevant improvement in pain significantly correlated with respective improvements in fatigue, depression, functional disability and tender joints (Table 2); worsening pain was negatively associated with change in disability or fatigue. <h3>Conclusions</h3> In Latinos with established RA, change in pain reporting reflects alterations in non-inflammatory parameters such as fatigue, depression and functional disability rather than inflammation. Active screening and consideration of those factors may inform therapeutic interventions, balance patient and physician expectations, and optimize patient satisfaction and clinical outcomes. <h3>Disclosure of Interest</h3> None declared